Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZX-4081 in Advanced Solid Tumors
NCT05118841Phase 1Unknown
- Sponsor
- Zenshine Pharmaceuticals Co., Ltd.
- Start
- Jan 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ZX-4081 in solid tumor (7 arms), sponsored by Zenshine Pharmaceuticals Co., Ltd. Primary endpoints: Recommended Phase 2 Dose and Safety and Tolerability of ZX-4081 up to 2 years. Status: unknown.
02
Drugs
ZX-4081
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05118841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05118841.